1,4-Dihydropyridines (DHPs) are widely recognized as a highly effective class of L-type calciumchannelblockers that offer significant therapeutic potential in managing cardiovascular conditions. Furthermore, their ability to target other types of calciumchannels makes DHPs attractive candidates for therapeutic applications in neurological and psychiatric disorders. Close examination of the chemical